US FDA rescinds market denial order for Juul products
Send a link to a friend
[June 07, 2024]
(Reuters) -The U.S. Food and Drug Administration (FDA) said on
Thursday it was rescinding a June 2022 order that briefly blocked sale
of Juul Lab's products, including its e-cigarette device.
The latest move comes a few months after Juul sought an FDA
authorization for new menthol-flavored pods meant to be used with its
e-cigarette device, which was under the agency's review.
The FDA in June 2022 banned Juul's four varieties of tobacco and
menthol-flavored pods and the e-cigarette device after it concluded that
the company failed to show that sale of these products would be
appropriate for public health.
The ban was stayed a month later after an appeal by the company.
The FDA said rescission of orders that prevent marketing of the products
is not an authorization or a denial of Juul's marketing application. The
revocation only returns company's applications to a pending and
under-review status.
"We appreciate the FDA's decision and now look forward to re-engaging
with the agency on a science and evidence-based process to pursue a
marketing authorization for Juul products," Juul said in a statement to
Reuters.
The marketing denial orders issued by the FDA have faced multiple
challenges in different U.S. states by the e-cigarette makers.
[to top of second column]
|
Juul e-cigarettes are seen on the counter of a vape store in Santa
Monica, California, U.S., June 23, 2022. REUTERS/Lucy Nicholson
"Some of these court decisions
establish new case law and inform the FDA's approach to product
review," the FDA said.
The agency began regulating e-cigarette devices and vapes in August
2016. So far, 23 e-cigarette products have been authorized by it for
sale in the United States.
The FDA said continued review of Juul's application does not alter
the fact that all e-cigarette products need its authorization to be
legally marketed.
(Reporting by Juveria Tabassum, additional reporting by Emma Rumney
in London; Editing by Mohammed Safi Shamsi and Vijay Kishore)
[© 2024 Thomson Reuters. All rights reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |